Replies to post #356591 on Amarin Corp Plc (AMRN)

[Number sleven]

Raf, Thanks for the numbers.
Sleven,

[Anilkhera]

Thank you Raf!!

[Examiner77]

Thank you Raf!
If my calculations are right, we have a 7% increase in scripts compared to Q2
Captbeer can confirm

[ralphey]

Am I seeing perhaps a glimmer of hope or do I misread the tea leaves


New Rx's for Vascepa are down 151 New Rx for gV are down 189 - does this mean there is less infringement occurring ?

[rafunrafun]

Scripts for week ending October 8, 2021

Overall drug TRx are +0.7% w/w

Vascepa
TRx 81,073; -0.2% (-126) w/w; -8.5% y/y
NRx 36,634; -1.6% (-609) w/w; -11.7% y/y
Ref 44,439; +1.1% (+483) w/w; -5.6% y/y

Lovaza (Generic & Brand)
TRx 64,468; +2.1% (+1,332) w/w; +6.2% y/y
NRx 31,457; +1.2% (+371) w/w; +2.4% y/y
Ref 33,012; +3.0% (+961) w/w; +10.1% y/y

Generic Vascepa
TRx 19,148; +3.0% (+557) w/w; As % of total V: 19.1%
NRx 10,958; +3.7% (+390) w/w; As % of total V: 23.0%
Ref 8,190; +2.1% (+167) w/w; As % of total V: 15.6%

Generic Vascepa by Manufacturer
Hikma - TRx 12,781 (+650); Generic share 66.7%; Total V share 12.8%
Reddy - TRx 6,368 (-92); Generic share 33.3%; Total V share 6.4%

TRx Vascepa + Generic Vascepa: 100,221 (+431)